American Journal of Cardiology
Volume 105, Issue 8 , Pages 1112-1117 , 15 April 2010

Differential Effects of Statins (Pravastatin or Simvastatin) on Ventricular Ectopic Complexes: Gαi2, a Possible Molecular Marker for Ventricular Irritability

  • C. Michael Welzig, MD, PhD

      Affiliations

    • Department of Neurosciences, Medical University of South Carolina, Charleston, South Carolina
    • Drs. Welzig and Park contributed equally to this work.
    • ,
  • Ho-Jin Park, PhD

      Affiliations

    • Molecular Cardiology Research Institute, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts
    • Drs. Welzig and Park contributed equally to this work.
    • ,
  • Jack Naggar, BA

      Affiliations

    • Molecular Cardiology Research Institute, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts
    • ,
  • Deborah Confalone, RN, MS

      Affiliations

    • Cardiology Division, Department of Medicine, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts
    • ,
  • Joanne Rhofiry

      Affiliations

    • Pharmacy Service, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts
    • ,
  • Julie Shea, MS, RNCS

      Affiliations

    • Department of Medicine, Brigham and Woman's Hospital, Boston, Massachusetts
    • ,
  • Richard H. Karas, MD, PhD

      Affiliations

    • Molecular Cardiology Research Institute, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts
    • Cardiology Division, Department of Medicine, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts
    • ,
  • N.A. Mark Estes III, MD

      Affiliations

    • Cardiology Division, Department of Medicine, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts
    • ,
  • Jonas B. Galper, MD, PhD

      Affiliations

    • Molecular Cardiology Research Institute, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts
    • Cardiology Division, Department of Medicine, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts
    • Corresponding Author InformationCorresponding author: Tel: 617-636-9004; fax: 617-636-4833

Received 17 August 2009 ,Revised 1 December 2009 ,Accepted 1 December 2009.

References 

  1. Vyas AK, Guo H, Moss AJ, Olshansky B, McNitt SA, Hall WJ, et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol. 2006;47:769–733
  2. Mitchell LB, Powell JL, Gillis AM, Kehl V, Hallstrom AP. Are lipid-lowering drugs also antiarrhythmic drugs? (An analysis of the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial). J Am Coll Cardiol. 2003;42:81–87
  3. De Sutter J, Tavernier R, De Buyzere M, Jordaens L, De Backer G. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol. 2000;36:766–772
  4. Goldberger JJ, Subacius H, Schaechter A, Howard A, Berger R, Shalaby A, et al. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1228–1233
  5. Schwartz PJ, La Rovere MT, Vanoli E. Autonomic nervous system and sudden cardiac death (Experimental basis and clinical observations for post-myocardial infarction risk stratification). Circulation. 1992;85:177–191
  6. Schwartz PJ, Zipes DP. Autonomic modulation of cardiac arrhythmias. In:  Zipes DP,  Jalife J editor. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia, Pennsylvania: W. B. Saunders; 2000;p. 300–314
  7. Kiuchi K, Shannon RP, Komamura K, Cohen DJ, Bianchi C, Homcy CJ, et al. Myocardial beta-adrenergic receptor function during the development of pacing-induced heart failure. J Clin Invest. 1993;91:907–914
  8. Lerman BMS, Mittal S, Iwai S. Ventricular Tachycardia in Structurally Normal Hearts. In: Philadelphia, Pennsylvania: W. B. Saunders; 2004;p. 668–682
  9. Welzig CM, Shin DG, Park HJ, Kim YJ, Saul JP, Galper JB. Lipid lowering by pravastatin increases parasympathetic modulation of heart rate: Galpha(i2), a possible molecular marker for parasympathetic responsiveness. Circulation. 2003;108:2743–2746
  10. Hughes A, Rogers MJ, Idris AI, Crockett JC. A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo. Calcif Tissue Int. 2007;81:403–413
  11. Eckernas SA, Roos BE, Kvidal P, Eriksson LO, Block GA, Neafus RP, et al. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia. Br J Clin Pharmacol. 1993;35:284–289
  12. Freeman R, Saul JP, Roberts MS, Berger RD, Broadbridge C, Cohen RJ. Spectral analysis of heart rate in diabetic autonomic neuropathy (A comparison with standard tests of autonomic function). Arch Neurol. 1991;48:185–190
  13. Anderson KP. Lipid-lowering therapy for prevention of ventricular tachyarrhythmias. J Am Coll Cardiol. 2003;42:88–92
  14. Schwartz PJ, Billman GE, Stone HL. Autonomic mechanisms in ventricular fibrillation induced by myocardial ischemia during exercise in dogs with healed myocardial infarction (An experimental preparation for sudden cardiac death). Circulation. 1984;69:790–800
  15. Cole CR, Blackstone EH, Pashkow FJ, Snader CE, Lauer MS. Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med. 1999;341:1351–1357
  16. Cole CR, Foody JM, Blackstone EH, Lauer MS. Heart rate recovery after submaximal exercise testing as a predictor of mortality in a cardiovascularly healthy cohort. Ann Intern Med. 2000;132:552–555
  17. Kataoka M, Ito C, Sasaki H, Yamane K, Kohno N. Low heart rate variability is a risk factor for sudden cardiac death in type 2 diabetes. Diabetes Res Clin Pract. 2004;64:51–58
  18. Donahue JK, Heldman AW, Fraser H, McDonald AD, Miller JM, Rade JJ, et al. Focal modification of electrical conduction in the heart by viral gene transfer. Nat Med. 2000;6:1395–1398
  19. Haigh LS, Leatherman GF, O'Hara DS, Smith TW, Galper JB. Effects of low density lipoproteins and mevinolin on cholesterol content and muscarinic cholinergic responsiveness in cultured chick atrial cells (Regulation of levels of muscarinic receptors and guanine nucleotide regulatory proteins). J Biol Chem. 1988;263:15608–15618
  20. Liang BT, Hellmich MR, Neer EJ, Galper JB. Development of muscarinic cholinergic inhibition of adenylate cyclase in embryonic chick heart (Its relationship to changes in the inhibitory guanine nucleotide regulatory protein). J Biol Chem. 1986;261:9011–9021
  21. Eschenhagen T, Mende U, Diederich M, Hertle B, Memmesheimer C, Pohl A, et al. Chronic treatment with carbachol sensitizes the myocardium to cAMP-induced arrhythmia. Circulation. 1996;93:763–771
  22. Park HJ, Georgescu SP, Du C, Madias C, Aronovitz MJ, Welzig CM, et al. Parasympathetic response in chick myocytes and mouse heart is controlled by SREBP. J Clin Invest. 2008;118:259–271

 This study was supported by an unrestricted grant from Bristol-Myers Squibb, New York, New York.

 Dr. Karas has received a research grant from AstraZeneca, Wilmington, Delaware, and is a member of the speakers bureau of Merck & Company, Whitehouse Station, New Jersey. Dr Estes: Tufts Medical Center has received educational grants from Boston Scientific Corporation, Natick, Massachusetts, Medtronic, Inc., Minneapolis, Minnesota and St. Jude Medical, Minneapolis, Minnesota, for EP fellowship funding. Dr. Estes serves on the Executive Committee of the MADIT-CRT and MADIT-RIT studies supported by Boston Scientific. No compensation. He has received honoraria for educational symposia from Boston Scientific.

PII: S0002-9149(09)02839-2

doi: 10.1016/j.amjcard.2009.12.011

American Journal of Cardiology
Volume 105, Issue 8 , Pages 1112-1117 , 15 April 2010

Article Tools

* Image Usage & Resolution